Search research articles
Contact Us
Filters
Showing results (401-410 of 481) with videos related to
Page
of 49
Sort By:
JCO Clinical Cancer Informatics
|
October 22, 2019
Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes
Gian Maria Zaccaria, Simone Ferrero, Samanta Rosati, et al.
Haematologica
|
February 24, 2018
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial
Riccardo Bomben, Simone Ferrero, Tiziana D'Agaro, et al.
British Journal of Haematology
|
January 21, 2021
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL)
Carola Boccomini, Marco Ladetto, Luigi Rigacci, et al.
Haematologica
|
March 24, 2018
Highly sensitive <i>MYD88</i><sup>L265P</sup> mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia
Daniela Drandi, Elisa Genuardi, Irene Dogliotti, et al.
Hemasphere
|
February 20, 2020
Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study
Lucia Morello, Sara Rattotti, Laura Giordano, et al.
Haematologica
|
January 14, 2017
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi
Francesco Zaja, Simone Ferrero, Caterina Stelitano, et al.
Hematological Oncology
|
July 21, 2019
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network
Irene Della Starza, Marzia Cavalli, Lucia Anna De Novi, et al.
Eclinicalmedicine
|
October 2, 2023
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
Urban Novak, Martin Fehr, Sämi Schär, et al.
Oncotarget
|
October 26, 2016
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis
Stefania Oliva, Manuela Gambella, Milena Gilestro, et al.
Bone Marrow Transplantation
|
July 8, 2021
Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term
Sergio Cortelazzo, Michael Mian, Andrea Evangelista, et al.
Page
of 49
Search research articles
Search
Showing results (401-410 of 481) with videos related to
Sort By:
Page
of 49
JCO Clinical Cancer Informatics
|
October 22, 2019
Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes
Gian Maria Zaccaria, Simone Ferrero, Samanta Rosati, et al.
Haematologica
|
February 24, 2018
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial
Riccardo Bomben, Simone Ferrero, Tiziana D'Agaro, et al.
British Journal of Haematology
|
January 21, 2021
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL)
Carola Boccomini, Marco Ladetto, Luigi Rigacci, et al.
Haematologica
|
March 24, 2018
Highly sensitive <i>MYD88</i><sup>L265P</sup> mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia
Daniela Drandi, Elisa Genuardi, Irene Dogliotti, et al.
Hemasphere
|
February 20, 2020
Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study
Lucia Morello, Sara Rattotti, Laura Giordano, et al.
Haematologica
|
January 14, 2017
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi
Francesco Zaja, Simone Ferrero, Caterina Stelitano, et al.
Hematological Oncology
|
July 21, 2019
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network
Irene Della Starza, Marzia Cavalli, Lucia Anna De Novi, et al.
Eclinicalmedicine
|
October 2, 2023
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
Urban Novak, Martin Fehr, Sämi Schär, et al.
Oncotarget
|
October 26, 2016
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis
Stefania Oliva, Manuela Gambella, Milena Gilestro, et al.
Bone Marrow Transplantation
|
July 8, 2021
Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term
Sergio Cortelazzo, Michael Mian, Andrea Evangelista, et al.
Page
of 49